Skip to main content

New Definition of Steatotic Liver Disease Improves Prediction of Kidney Disease

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 20, 2024.

By Lori Solomon HealthDay Reporter

TUESDAY, Aug. 20, 2024 -- Using a new classification of steatotic liver disease (SLD) based on the presence of metabolic dysfunction and alcohol consumption, metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD) are significantly associated with the new onset of chronic kidney disease (CKD), according to a study published online Aug. 7 in Hepatology Research.

Kazuma Mori, M.D., from the Sapporo Medical University School of Medicine in Japan, and colleagues investigated the effects of various SLDs on the development of CKD. The analysis included 12,138 Japanese individuals with annual health examinations that included abdominal ultrasonography during a 10-year period.

The researchers found that during follow-up, 16.2 percent of participants (17.2 percent of men; 14.2 percent of women) had new onset of CKD. When adjusting for age, sex, estimated glomerular filtration rate, current smoking habit, diabetes mellitus, hypertension, and dyslipidemia, the risk for developing CKD was elevated in individuals with MASLD and those with ALD versus those with non-SLD; however, no association was seen for those with MASLD and increased alcohol intake. Compared with those with non-SLD, participants with SLD without metabolic dysfunction had a significantly lower risk for CKD. The addition of the novel classification of SLDs into traditional risk factors for the development of CKD significantly improved discriminatory capacity.

"In clinical practice, it is possible to identify patients at high risk for CKD among those with SLD by classifying hepatic steatosis according to the new classification of SLDs," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted August 2024

Read this next

Metabolic Dysfunction-Linked Steatotic Liver Disease Tied to Increased Preterm Birth Risk

TUESDAY, May 20, 2025 -- Metabolic dysfunction-associated steatotic liver disease (MASLD) in pregnant women is a risk factor for preterm birth, according to a study published...

Study IDs Trends in 2015 to 2023 Mortality for Chronic Liver Disease

THURSDAY, May 8, 2025 -- Distinct trends were seen in etiology-based mortality with chronic liver disease (CLD) before, during, and after the COVID-19 pandemic, according to a...

Semaglutide Beneficial in Metabolic Dysfunction-Associated Steatohepatitis, Fibrosis

FRIDAY, May 2, 2025 -- For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.